Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
all-trans retinoic acid + vincristine + dactinomycin + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Children's Oncology Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of all-trans retinoic acid (ATRA), vincristine, dactinomycin, and cyclophosphamide. This regimen is being evaluated by Fudan University for the treatment of intermediate-to-high-risk rhabdomyosarcoma. ATRA, a derivative of vitamin A, acts as a differentiating agent by binding to retinoic acid receptors, potentially inducing the maturation of malignant cells. Vincristine is a vinca alkaloid that inhibits microtubule polymerization, disrupting mitotic spindle formation. Dactinomycin is a cytotoxic antibiotic that intercalates into DNA and inhibits RNA synthesis. Cyclophosphamide is an alkylating agent that forms DNA cross-links, leading to cell death. The combination aims to leverage the differentiation-inducing properties of ATRA alongside the cytotoxic effects of the standard VAC regimen to improve clinical outcomes in patients with rhabdomyosarcoma.
- Other names
- ATRA combined with VAC regimenATRA+VAC chemotherapy
02
Targets
DNARARA (Retinoic acid receptor alpha)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on all-trans retinoic acid + vincristine + dactinomycin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on all-trans retinoic acid + vincristine + dactinomycin + cyclophosphamide.